This painting company has been stable, but they have seen sustained growth and have been one of the fastest growing small business painting companies in the Vancouver/Portland area. Starting in 2013, annual had already eclipsed half a million by 2019. With a work-from-home office, this business provides the ability to manage safely out of your own home or to be able to choose your ideal location to rent. Strong customer ratings and consistently high levels of service have made this an ideal business for anyone looking to establish a presence in the painting industry or to expand your current painting business territory and customer base. Detailed Information Employees:2 FTE Support & Training: Seller will negotiate a transition period Reason for Selling: Relocation

The Company has proprietary technology that addresses a leading cause of maternal death (76,000) and fetal death (500,000) annually worldwide. 8% of pregnancies in the US and 14% worldwide have diagnoses that would be vastly improved by worldwide commercialization of the Company's proprietary device. A very low risk procedure that both provides quality of life improvement for the mother & baby and lowers health care costs is a win/win/win for all involved. Existing collaborations with major manufacturers coupled with a current expedited approval process with the FDA presents a tremendous opportunity for individuals or private equity groups seeking a transformative investment into a feel-good biotech story with exceptional legs and a vast runway with nearly unlimited upside. Able to work with groups/individuals in tranches of $500k to $1M to advance into the pilot clinical study, $2-$3MM for the pivotal clinical study towards market approval in the US. They will seek direct sales with partnered hospitals, licensing / partnership deals could utlimately yield the balance of funding to fully deploy a commercial version of the technology. NDA is required for comprehensive Confidential Information Memorandum (CIM) crafted by us. Detailed Information Competition: No current option available besides bed rest. Growth & Expansion: Huge market potential. Support & Training: Full team included. Reason for Selling: Seeking supportive capital partners to take to the next level(s). .

An exceptional opportunity to acquire a leading International Early Childhood Development Company, renowned for its pioneering integration of digital content in early childhood education, with a strong emphasis on social, emotional, and intellectual development. Programs are offered in more than 20 languages and have an impressive presence in more than 30 countries. The Company’s solid track record of meeting demand and creating growth is backed by an extensive franchise/license network. The Company’s proven teaching models produce exceptional results that have garnered high satisfaction ratings among children and parents alike. Independent research validates the superior outcomes achieved through exclusive age-based programs, enabling children to accelerate their learning levels twice as fast as their peers. The foundation of the Company’s success lies in its Licensing and Master Franchise structure. This highly effective framework enables them to meet local needs and rise above competition; adapting to diverse regional markets, and catering to cultural nuances. With plans for further expansion, the Company is poised to strengthen its position as a global leader in education. The Company has taken intellectual property protection seriously, employing robust safeguards to protect its 95 international trademarks, and 49+ copyrights, via a fortified software registration system. Don't miss this rare opportunity to acquire a thriving global Education Company with a proven model, and a commitment to innovation. Seize the chance to make a profound impact on children's lives while unlocking unlimited potential for growth and success. NDA is required 626to secure a comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners. Facilities: No facilities. It is all virtual. Competition: While operating in a fragmented industry with numerous competitors, what truly distinguishes this Company is its dedication to cultivating essential learning skills that can be universally applied across academic subjects, such as mathematics. By combining digital resources, interactive technology, curriculum development, and effective teaching methods, the Company has long been at the forefront of integrating digital content into early childhood learning. The result is consistently achieving remarkable outcomes and staying ahead of any competitor. Growth & Expansion: Numerous avenues for growth and expansion lie ahead, including: 1. Expand presence by appointing Master Franchisees in Latin America, Asia, and Africa. 2. Strengthen market coverage by adding franchisees to existing geographic territories. 3. Boost brand visibility through enhanced social media marketing strategies. 4. Enhance the current digital curriculum in alignment with the newest and most advanced technology platforms. 5. Explore opportunities to directly sell to US Schools, tapping into a mass market segment. 6. Capitalize on the demand for digital content by offering valuable resources to families. By pursuing these strategic initiatives, the Company can harness its potential for exponential growth and secure a prominent position in the industry. Financing: TBD if deal structure and terms are acceptable. Support & Training: To facilitate a seamless transition and ensure continued success, the Seller is committed to providing comprehensive training and is open to the possibility of remaining as an employee, subject to negotiation regarding salary, duration, and terms. Reason for Selling: The Seller believes that now is an opportune time to sell.

Patented Universal Tumor-Targeting Drug Delivery Platform Co. This pharmaceutical company has developed and patented a universal tumor-targeting drug-delivery platform that can improve the safety and efficacy of many existing chemo treatments, with the ability to target numerous different types of cancer. The technology encapsulates existing FDA-approved drugs inside lipid nanoparticles (liposomes or emulsions) coated with patented human-sourced antinuclear antibodies (ANA). The lipid nanoparticle provides long-term storage stability of the drug and controlled release of the drug over time at body-temperature, and is expected to improve the safety and efficacy profile of the drug, including passive accumulation at the tumor while not harming normal tissues. The Company's ANA, sourced from lupus patients, binds to nuclear material present in abundance in areas of necrosis (dead / ruptured cells) present in and around all solid tumors, thus anchoring the drug-filled nanoparticles at the tumor where the nanoparticle is designed to slowly release the drug directly on the tumor for more effect. As the Company's ANA is not tumor-marker specific, but rather targets necrosis present in solid tumors, the technology is designed to "universally" target many different types of cancer including breast cancer, lung, ovarian, colon, prostate, etc., as well as rare childhood cancers. The Company completed a successful proof-of-concept study at Children's Hospital using Ewing's Sarcoma transplanted in immunodeficient mice. Treatment with the Company's forumlation significantly inhibited tumor growth and extended survival times compared to control mice receiving no treatment or treatment with plain liposomal doxorubicin. The Company has been granted Orphan Drug Designation by the FDA on 2 of the lead drug formulations, providing FDA fee waivers, priority review, and 7-years exclusivity upon market approval. The orphan pathway also enables the potential for New Drug Approval after successful completion of Phase 2 studies, with Phase III data collected while in the market, thus significantly lowering the time and cost to market approval. This same drug inside the Company's tumor targeting delivery system will likely have potential to treat other pediatric cancers, and/or cancers in larger adult populations. As the Company's platform and ANA has the potential to improve the safety and efficacy of many existing FDA approved drugs or even compounds in development, the Company anticipates the potential for multiple licensing agreements with multiple pharmaceutical companies seeking to improve their existing portfolio and extend patient life as they advance into clinical stage. And as it may be possible to file for New Drug Approval following successful Phase II studies, the Company anticipates licensing potential at early clinical stage. Multiple exit opportunities exist with high impact & high ROI. The Company is seeking a supportive capital partner to maintain momentum up to $20M. Funding will be used to advance the lead drug through formal Investigational New Drug enabling studies towards New Drug Approval; estimating $3-5 Million now to advance into clinical studies. Preclinical / animal studies estimate ($3 - 5 Million and 12-18 months); follwed by potential combined Phase I-II clinical study in a rare cancer (approximately 2-3 years and $10M) to potential New Drug Approval, plus additional capital to advance additional drugs in the pipeline simultaneously, thus adding tremendous value to the Company's valuation. Valuations of pharma companies often exceed $100 Million valuation at Phase I (approx. 18 months), and New Drug Approval can exceed valuations above $1 Billion. The Company has numerous, improved high-impact cancer drugs advancing with proper support. NDA is required for comprehensive Confidential Information Memorandum crafted by ProNova Partners. Detailed Information Competition: Trying to improve existing therapies and develop novel approaches to hard to treat cancers. Growth & Expansion: Huge market potential. Financing: If the price and deal structure is right. Support & Training: Transition team included. Reason for Selling: Seeking supportive capital partners to take to the next level(s). .

This is a great chance to own a relaxed lifestyle business, helping tourists get to their luaus on time. The business has been around for 24 years, is licensed in the relevant county, and enjoys a great reputation. The current owner has elected to remain closed on Sundays, allowing for an immediate revenue increase for the motivated acquirer. While the opportunities for growth are capped geographically, the core business is very robust surviving the tourist downturn over the pandemic. There is currently demand growth on other parts of the island, for which a well-capitalized acquirer could begin servicing. The well-established drivers handle the majority of the rides, but if you enjoy chatting with people, you can always get behind the wheel yourself. Enjoy exploring the beautiful Hawaiian Island of Kauai, while on the clock! The seller has employed family in remote positions, some of whom are open to staying on, or the possibility of supplementing operations with software instead exists for an acquirer looking to improve operational efficiency. The seller is leaving the state but is open to helping an acquirer transition on their timeline. The numbers in this teaser are taken from the end of the year 2021. The Company has not maintained cash flow statements and the cash flow amount is estimated. Full access to Company financials is available with a Letter of Intent. NDA is required to receive a comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners. Detailed Information Facilities: Not included (their office has been run out of the family home) Competition: While ride-share apps are available on the island, scheduling consistent, reliable transportation for events, like luaus or airport trips is still commonly managed with taxi services. Growth & Expansion: The business is currently closed on Sundays, opening up operations on Sundays does provide additional revenue. Financing: TBD if structure and terms are acceptable. Support & Training: The seller wishes to provide for a successful transition of the business and is willing to provide transition support daily for up to four months. Reason for Selling: The seller is relocating to be with family and grandchildren.

Our client has an innovative blockchain platform that operates as a digital marketplace where users can create coins and smart contracts to trade assets, goods, and services using a digitally encrypted, peer-to-peer blockchain exchange system. With our client's platform, users can create, transact, and destroy any digital asset or smart contract in their personal E-Vault utilizing the Ethereum blockchain. In short, our client's platform essentially replaces traditional dependency upon third-party market vendors, such as banks, to make transactions or legally binding contracts. Our client's platform provides a unique capacity for users to easily create digital assets of their choosing to trade in a digital marketplace. With the addition of smart contracts, to provide functions such as mint/burn coin, automate interest rates, collateralize smart contracts, and much more. The value of an asset created by each user is set by the market value. The asset itself may be tangible, for example, a gold-backed digital coin or as intangible like time, such as volunteer or billable hours. Our client's software is run by a hybrid platform/blockchain Decentralized Autonomous Organization (DAO). There are 300 main Spartan Nodes that verify all transactions using similar technology to Solana's quick blockchain speeds by predesignating which node will solve which block. This allows more than 100,000 transactions per second making our client's software the fastest blockchain layer 2 solution that could easily compete with Visa/Mastercard along with the P2P transactions being free! Anyone can also download a node from our client that has the full history and syncs through the blockchain instantly but does not verify any transactions like the main 300 Spartan nodes do. Top 10 Features: 1. Decentralized Exchange w/ over 1,700+ coins 2. Lightning & (soon to be) Raiden Network offers FREE instant transactions 3. Create advanced ERC-20 tokens with imbedded DeFi smart contracts 4. Register ANY real world item as NFT on ETH 5. Create vital records such as birth certificates or last will 6. GNEISS network allows free text and soon free audio/video calls 7. History gives the ENTIRE transaction history for an Evault 8. Verify identity using BasisID with top biometrics in the world and (here soon) credit score 9. Coming soon - DeFi copy of AAVE and margin trading using it 10. Coming later - Multisig Wallets, DAOs, Airdrop, Voting, Swap, Betting, BTC & ETH block inscription) Our client's software is 'ready to go;' and is operating with customers and cash flow. NDA is required to secure comprehensive Confidential Information Memorandum (CIM). Detailed Information Facilities: N/A Growth & Expansion: Unlimited world wide. Financing: Sellers will consider, BitCoin preferred Support & Training: As needed specific terms for transition support can be negotiated. The Seller wishes to facilitate a successful and smooth transfer of the Business. Reason for selling: Expansion.

Confidential Information Memorandum (CIM) available upon receipt of our short online NDA. * It is estimated that the marketplace for connected cars and automobile data is will reach $400BN by 2030. * There are currently ~280MM registered automobiles in the US today with ~65MM of them being connected cars * The Company has created a process that while working with 3rd party Companies in the space and simultaneously creating a near proprietary technology is able to harness processes related to car data, thereby creating an opportunity for Companies looking to enter the aftermarket space for consumers and/or enterprises already in the automobile space, * Ideally this would be an add-on solution for any Company that is in the fleet-auto space, or looking to create an expansive and/or sweeping platform for the Consumer space NDA is required to secure comprehensive Confidential Information Memorandum (CIM). Detailed Information: Facilities: Home Based Competition: Few if any Growth & Expansion: Ample Financing: Depending on offer and structure may be acceptable minimal if any Support & Training: As needed. Reason for Selling: Existing opportunities

Our client operates a lean, high-margin B2B lead-generation platform dedicated to the Internet of Things sector. By leveraging a permission-based community of over 60,000 vetted IoT decision-makers and a LinkedIn Group of 20,000+ approved professionals, they deliver turnkey sponsored webinars, white-paper campaigns, and targeted email blasts—providing technology vendors with consistently qualified leads while maintaining minimal overhead through a fully remote, contractor-driven model. NDA is required for comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.